CURRICULUM VITAE - Amyloidosis Support



CURRICULUM VITAE

NAME: Jonathan Kaufman, MD

OFFICE ADDRESS: Emory University

Winship Cancer Institute

1365 Clifton Road, Building C

Suite C2096

Atlanta, GA 30322

Phone: 404-778-1814

Fax: 404-778-5530

EMAIL ADDRESS: Jonathan.Kaufman@

Current Titles and Affiliations:

07/2005-Present Assistant Professor

Department of Hematology and Oncology

Winship Cancer Institute

Emory University School of Medicine

Education

Undergraduate

08/1990-06/1994 University of Florida, Gainesville, Florida

Bachelor of Science (with honors)

Medical School

08/1995-05/1999 Medical College of Georgia, Augusta, Georgia

M.D.

Postgraduate Training

07/1999-06/2001 Internal Medicine Resident

Emory University School of Medicine*

*American Board of Internal Medicine Clinical Investigator Pathway

06/2001-06/2004 Hematology and Oncology Fellow

Winship Cancer Institute

Emory University School of Medicine

07/2004-06/2005 Hematology and Oncology Chief Fellow

Winship Cancer Institute

Emory University School of Medicine

Administrative Memberships:

10/2007-Present Institutional Review Board (IRB)

Society Memberships:

American Society of Hematology

American Society of Clinical Oncology

Honors and Awards

07/1999-06/2000 Best Resident in Internal Medicine

07/2001-06/2005 Edwin M. Crissey Fellowship/Hematology and Oncology

Winship Cancer Institute

Emory University School of Medicine

12/2005 ASBMT Young Investigator Travel Grant.

Tandem BMT Meetings

08/2005 ASCO/AACR Methods in Clinical Cancer Research

Specialty Boards

08/2002-12/2012 Board Certified Internal Medicine

11/2005-12/2015 Board Certified Hematology

11/2005-12/2015 Board Certified Medical Oncology

Leaderships, Seminar Invitations and Visiting Professorships:

05/2005 Kaufman, JL. Toward a cure for multiple myeloma: Targeting the microenvironment and myeloma interaction. Winship Cancer Institute’s Director’s Seminar.

05/2006 Kaufman, JL. Anaplastic Large Cell Lymphoma (ALCL): A Review Investigator’s Meeting MDX-060-04. Dublin, Ireland.

10/2006 Kaufman, JL. Amyloidosis: The Old and the new. Winship Cancer Institute, Grand Rounds.

08/2007 Kaufman, JL. Amyloidosis: Future Directions in Hematology and Oncology. Sea Island, Georgia.

08/2007 Kaufman, JL. Monoclonial Antibodies in Multiple Myeloma. 7th International Congress on Monoclonial Antibodies in Cancer. Quebec, Canada

National and Intrnational Conference Invitations

2001 Kaufman, JL. Lung Cancer in a Young Patient. Southern Society of General Internal Medicine.

2005 Kaufman, JL, Lonial S, Hicks M, Langston A, Flowers C, Lechowicz MJ, Khoury H, Waller EK. Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma. Tandem (ASBMT/CIBMTR) BMT Meetings. Abstract 17.

2005 David E, Kaufman, JL, Sun S-Y, Khuri F, Lonial S. The combination of Tipifarnib and Bortezomib Results in Synergistic Myeloma Cell Death Via Downregulation of Phospho-AKT and Induction of Apoptosis. (Oral Presentation, 10th International Myeloma Workshop).

Bibliography:

Published and accepted Journal Research Articles:

1. Kaiser WJ, Kaufman JL and Offermann MK. IFN-alpha sensitizes human umbilical vein endothelial cells to apoptosis induced by double-stranded RNA. The Journal of Immunology. 2004 Feb 1. 172(3):1699-710.

2. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J and Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007 Mar 15; 109(6):2604-6.

3. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK and Kaufman JL. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion. 2007 Apr; 47(4):629-35.

4. Mazumder A, Kaufman JL, Niesvizky R, Lonial S, Vesole D and Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2007 Nov; 22. (In Press).

5. Gladney SP, Lonial S and Kaufman JL. Multiple Myeloma Presenting with Advanced Renal Failure: A Case Report and New Treatment Options. Clinical Lymphoma & Myeloma. 2007 Nov (Accepted for Publication).

Review Articles:

1. Kaufman JL and Lonial S. Multiple Myeloma: the role of transplant and novel treatment strategies. Seminars in Oncology. 2004 Apr;31 (2 Supplement 4):99-105.

2. Kaufman JL and Lonial S. Review of New Treatment for Multiple Myeloma. Oncology, 2005 Dec.

3. Sinha R, Kaufman JL, Lonial S. Novel treatment approaches for patients with Multiple Myeloma. Clinical Lymphoma Myeloma. 2006 Jan;6(4):281-8.

4. Kaufman JL and Lonial S. Proteasome Inhibition: Novel Therapy for Multiple Myeloma. Onkologie 2006 Apr;29:162-168.

5. Mihelic R, Kaufman JL and Lonial S. Maintenance therapy in multiple myeloma. Leukemia. 2007 Jun;21(6):1150-7. Epub 2007 Mar 8.

6. Mihelic R, Kaufman J, Lonial S, Flowers C. Maintenance therapy in lymphoma. Clinical Lymphoma Myeloma. 2007 Sep; 7(8):507-13.

Book Chapters:

1. Kaufman JL, Mihelic R and Lonial S, “Maintenance Therapy in Myeloma”, Pursuing the Plasma Cell: Therapeutic Advances in Myeloma Therapy. Completed; Under contract with Humana Press.

Manuscripts Submitted:

1. David E, Sinha R, Chen J, Sun Shi-Yong, Kaufman JL, Lonial S. Trail synergistically enhances perifosine induced myeloma cell apoptosis via upregulation of death receptors. Submitted to Clinical Cancer Research

Abstracts:

1. Kaufman JL, Lonial S, Hicks M, Langston A, Flowers C, Lechowicz MJ, Khoury H, Waller EK. Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma. February 2005, Supplement 1, (11.2) 6.

2. Asher Alban Chanan-Khan, P. Richardson, S. Lonial, D. Siegel, S. Kaufman JL, Jagannath, J. Mehta, J. Doran, S. Singhal. Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis. Blood November 16, 2005; 106; 11; 716a.

3. Jonathan L. Kaufman, Ebenezer David, Claire Torre, Rajni Sinha, Sagar Lonial. Enhanced Levels of Apoptosis by Combination of Farnesyl Transferase Inhibition (Tipifarnib) and Proteasome Inhibition (Bortezomib) in Myeloma Cell Lines and Primary Myeloma Cells and Its Mechanistic Effects on Akt and Caspase Pathways. Blood November 16, 2005; 106; 11; 451a.

4. Rajni Sinha, Ebenezer David, Emily Zeilter, Claire Torre, Jonathan L. Kaufman, Sagar Lonial. Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines. Blood November 16, 2005; 106; 11; 450a.

5. Ebenezer David, Rajni Sinha, Claire Torre, Jonathan L. Kaufman, Sagar

Lonial. Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines. Blood November 16, 2005; 106; 11; 428a.

6. Amy S. Lucas, Christopher Flowers, Amelia Langston, Sagar Lonial, Mary Jo Lechowicz, Ned Waller, Jonathan L. Kaufman, and H. Jean Khoury. Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 3065.

7. Ethan Tolbert, Ned Waller, H. Jean Khoury, Mary Jo Lechowicz, Christopher Flowers, Sagar Lonial, Laura Vann, Amelia Langston, and Jonathan L. Kaufman Infliximab for the Treatment of Chronic Graft Versus Host Disease. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2889.

8. Ebenezer David, Rajni Sinha, Jonathan L. Kaufman, and Sagar Lonial

Perifosine Induces DR4/DR5 Expression Leading to Apoptosis That Can Be Enhanced with Exogenous TRAIL, and Blocked with Strategies Directed at DR4/DR5 Inhibition. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 3446.

9. Kaufman JL, Gleason C, Heffner LT, Langston AA, Waller EK, Lonial S. Bortezomib, Thalidomide and Dexamethasone as Induction XIth International Myeloma Workshop.

10. Lonial S, Kaufman J, Langston AA, Heffner LT, Torre C, Lechowicz MJ, Flowers C, McMillan S, Arnold M, Waller NK. A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 949.

11. Andrzej J, Zimmerman T, Alsina M, Richardson P, Kaufman J, Kendall T, Brozo C, McAllister A, Leister C, Hideshima T, Sportelli P, Gardner L, Birch R, Henderson IC, Guisti K and Anderson K. A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1169.

12. Ebenezer D, Schafer-Hales, K, Marcus, AI, Kaufman J and Lonial S. Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1520.

13. Kaufman J, Cook AM, Flowers C, Langston AA, Lonial S, Lechowicz MJ, Khoury HJ, Calandra G and Waller N. The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1912.

14. Kaufman JL, Gleason C, Heffner L and Lonial S. Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3605.

15. Mazumder A, Kaufman J, Lonial S, Jagannath S and Vesole D. Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 3612.

Clinical Trials (Principal Investigator):

1. AMD3100-3102 07/07/2006

AnorMED

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240μg/kg) plus G-CSF (10μg/kg) Versus G-CSF (10μg/kg) Plus Placebo to Mobilize and Collect> 6 x 106 CD34+ Cells/KG in Multiple Myeloma Patients for Autologous Transplantation

2. AMD3100-3102-LTF 10/25/2006

Genzyme

Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 mu g/kg) Plus G-CSF (10 mu g/kg) Plus Placebo to Mobilize and Collect ≥ 6 x 1,000,000 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation

3. AMD3100-CUP001 05/10/2007

Genzyme

Compassionate Use Protocol for the use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation.

4. 3129K3-101-WW 07/10/2007

Wyeth

A Phase 1/2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

5. PX-171-004 09/17/2007

An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma.

6. IMMU-115-01 10/26/2007

Immunomedics,

A Phase I/II Study of Immunotherapy with hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients with Multiple Myeloma

7. SG0400005 10/29/2007

Seattle Genetics

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) With and Without SGN-040 (Anti-C Humanized Monoclonal Antibody) for Second-Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

8. AOI127 11/02/2007

WCI

An Open-Label Phase I Study of the Safety of Perifosine in Combination with Lenalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

9. KAG-302 11/08/2007

Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Comparing Three Doses of Tanespimycin in Patients with Relapsed-Refractory Multiple Myeloma

10. MDX1401-01 12/03/2007

Medarex

A Phase I, Open-Label, Dose-Escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients with CD30 Positive Refractory/Relapsed Hodgkin's Lymphoma.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download